A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 247 participants.
Also called NCT03751657
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 247 participants
- Sponsor
- Registry
-
NCT03751657 -
2018-000322-63
-
- Other papers using this trial's data
- Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Czechia, Greece, Poland, Slovakia, Slovenia
- Registry status
- Completed
Technical summary
Registry record NCT03751657. Randomized; quadruple masking; primary purpose treatment. Start 2018-11-29 (actual); primary completion 2019-12-16 (actual). Results posted on 2021-02-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Insulin icodec
- Intervention (Drug)
- Placebo (insulin 287)
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Dipeptidyl peptidase-4 inhibitors
- Intervention (Drug)
- Insulin glargine
- Intervention (Drug)
- Placebo (insulin glargine)
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct03751657- Content hash
8f0e8b9d21d697619fb1e305e30319294d11346bef4b7d5f9ef9212e5c9bee5b